Creative Financial Designs Inc. ADV raised its holdings in shares of Quest Diagnostics Incorporated (NYSE:DGX – Free Report) by 3,310.0% in the first quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 341 shares of the medical research company’s stock after buying an additional 331 shares during the period. Creative Financial Designs Inc. ADV’s holdings in Quest Diagnostics were worth $48,000 as of its most recent SEC filing.
A number of other large investors have also recently added to or reduced their stakes in DGX. Vanguard Group Inc. boosted its stake in Quest Diagnostics by 4.8% in the 1st quarter. Vanguard Group Inc. now owns 14,014,030 shares of the medical research company’s stock worth $1,917,961,000 after purchasing an additional 636,301 shares during the period. Victory Capital Management Inc. boosted its stake in Quest Diagnostics by 1.1% in the 4th quarter. Victory Capital Management Inc. now owns 3,258,465 shares of the medical research company’s stock worth $509,754,000 after purchasing an additional 34,947 shares during the period. Northern Trust Corp boosted its stake in Quest Diagnostics by 0.6% in the 1st quarter. Northern Trust Corp now owns 1,514,577 shares of the medical research company’s stock worth $207,286,000 after purchasing an additional 8,406 shares during the period. Amundi boosted its stake in Quest Diagnostics by 7.7% in the 4th quarter. Amundi now owns 1,475,354 shares of the medical research company’s stock worth $228,663,000 after purchasing an additional 105,471 shares during the period. Finally, Price T Rowe Associates Inc. MD boosted its stake in Quest Diagnostics by 548.7% in the 2nd quarter. Price T Rowe Associates Inc. MD now owns 1,125,530 shares of the medical research company’s stock worth $149,673,000 after purchasing an additional 952,037 shares during the period. 87.39% of the stock is currently owned by institutional investors.
Analyst Ratings Changes
A number of equities analysts recently commented on the stock. Truist Financial decreased their price objective on shares of Quest Diagnostics from $170.00 to $160.00 and set a “hold” rating for the company in a research note on Friday, March 17th. StockNews.com started coverage on shares of Quest Diagnostics in a research report on Thursday, May 18th. They issued a “hold” rating for the company. Bank of America downgraded shares of Quest Diagnostics from a “buy” rating to a “neutral” rating and cut their target price for the stock from $166.00 to $148.00 in a research report on Tuesday, May 2nd. Piper Sandler started coverage on shares of Quest Diagnostics in a research report on Thursday, June 29th. They issued a “neutral” rating for the company. Finally, Citigroup upgraded shares of Quest Diagnostics from a “sell” rating to a “neutral” rating and increased their target price for the stock from $125.00 to $142.00 in a research report on Monday, April 3rd. Ten investment analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus price target of $151.20.
Quest Diagnostics Stock Down 0.1 %
Quest Diagnostics (NYSE:DGX – Get Free Report) last released its quarterly earnings results on Thursday, April 27th. The medical research company reported $2.04 earnings per share for the quarter, beating analysts’ consensus estimates of $1.97 by $0.07. The business had revenue of $2.33 billion for the quarter, compared to the consensus estimate of $2.20 billion. Quest Diagnostics had a net margin of 8.26% and a return on equity of 16.51%. Quest Diagnostics’s revenue for the quarter was down 10.7% on a year-over-year basis. During the same quarter last year, the firm earned $3.22 EPS. Sell-side analysts forecast that Quest Diagnostics Incorporated will post 8.69 earnings per share for the current fiscal year.
Quest Diagnostics Announces Dividend
The company also recently announced a quarterly dividend, which will be paid on Tuesday, July 25th. Investors of record on Tuesday, July 11th will be issued a $0.71 dividend. The ex-dividend date of this dividend is Monday, July 10th. This represents a $2.84 annualized dividend and a yield of 2.02%. Quest Diagnostics’s dividend payout ratio (DPR) is presently 41.89%.
Quest Diagnostics Profile
Quest Diagnostics Incorporated provides diagnostic testing, information, and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine testing, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services.
Featured Articles
- Five stocks we like better than Quest Diagnostics
- Delta Takes Flight: Double-Digit Upside In Sight
- Generac Powers Up as Summer Temperatures Rise
- 3 Reasons Why Rivian Can Continue To Surge Higher
- Despite Breaking Higher, Analysts Remain Cautious HP Inc.
- PepsiCo Can Soar To New Highs In The 2nd Half
Receive News & Ratings for Quest Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quest Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.
